Oxford Spinout Alethio Raises $90M Series A for a G6b Antibody in Essential Thrombocythemia
- Alethio Therapeutics, an Oxford spinout founded by Adam Mead and Beth Psaila, raised a $90 million Series A co-led by Sofinnova Partners and RA Capital.
- Lead asset ATX-011 is a preclinical monoclonal antibody against G6b, a receptor on platelets and some marrow cells, intended to work regardless of the driver mutation; clinic entry is guided for the first half of 2028.
- A second candidate, an ADC for myelofibrosis, is also in development.
💡 Points Based on public reports
A $90 million round for an asset that won't dose a patient until 2028 is a bet on the mutation-agnostic idea: today's therapies mostly target JAK2-driven biology or the mutant clones, and calreticulin-directed antibodies are the obvious comparison. The thing to watch is whether a platelet-lineage receptor can be hit without thrombocytopenia or bleeding. Essential thrombocythemia is a large, long-lived population, which is what makes the commercial case.